- Home
- OP vs CDIO Comparison
OP vs CDIO Comparison
Compare OP & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- CDIO
- Stock Information
- Founded
- OP 2021
- CDIO 2017
- Country
- OP Greece
- CDIO United States
- Employees
- OP N/A
- CDIO N/A
- Industry
- OP
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- OP
- CDIO Health Care
- Exchange
- OP Nasdaq
- CDIO Nasdaq
- Market Cap
- OP 5.3M
- CDIO 7.9M
- IPO Year
- OP N/A
- CDIO N/A
- Fundamental
- Price
- OP $1.84
- CDIO $3.61
- Analyst Decision
- OP
- CDIO Buy
- Analyst Count
- OP 0
- CDIO 1
- Target Price
- OP N/A
- CDIO $60.00
- AVG Volume (30 Days)
- OP 9.3M
- CDIO 56.5K
- Earning Date
- OP 08-06-2025
- CDIO 08-11-2025
- Dividend Yield
- OP N/A
- CDIO N/A
- EPS Growth
- OP N/A
- CDIO N/A
- EPS
- OP N/A
- CDIO N/A
- Revenue
- OP $25,702,000.00
- CDIO $19,902.00
- Revenue This Year
- OP N/A
- CDIO $1,434.82
- Revenue Next Year
- OP N/A
- CDIO $4,661.91
- P/E Ratio
- OP N/A
- CDIO N/A
- Revenue Growth
- OP 35.58
- CDIO N/A
- 52 Week Low
- OP $0.63
- CDIO $3.22
- 52 Week High
- OP $3.17
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- OP 55.66
- CDIO 32.36
- Support Level
- OP $1.82
- CDIO $3.65
- Resistance Level
- OP $2.30
- CDIO $4.18
- Average True Range (ATR)
- OP 0.51
- CDIO 0.31
- MACD
- OP 0.02
- CDIO 0.12
- Stochastic Oscillator
- OP 46.59
- CDIO 4.49
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.